Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828054) titled 'Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan' on Sept. 14.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Mario Negri Institute for Pharmacological Research
Condition:
Breast Cancer
Interstitial Lung Disease (ILD)
Intervention:
Drug: Dexamethasone
Drug: antiemetic premedication
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: December 20, 2026
Target Sa...